Connective tissue disorders and cardiac arrhythmias: genetic pathways, mechanistic bridges, and clinical implications
Frontiers in Cardiovascular Medicine · 03.09.2026 · 13
DOI: 10.3389/fcvm.2026.1860012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 03.09.2026. Verfasst von Luke Dreher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Connective tissue disorders (CTDs) such as Marfan syndrome, Loeys-Dietz syndrome, and Ehlers-Danlos syndromes are traditionally defined by vascular fragility and aortic complications. Increasing evidence, however, demonstrates that CTDs also predispose to atrial and ventricular arrhythmias, often independent of overt cardiomyopathy or severe valvular disease. Content This review integrates emerging data on the arrhythmogenic substrates of CTDs. Four mechanistic bridges are emphasized: (1) diffuse myocardial fibrosis driven by dysregulated TGF-β signaling, (2) structural valve and annular abnormalities, particularly mitral valve prolapse and mitral annular disjunction, (3) altered mechanotransduction linking extracellular matrix instability to cytoskeletal and nuclear signaling pathways, and (4) downstream ion-channel and gap-junction remodeling as secondary amplifiers. We outline the genetic architecture underlying these processes, focusing on established CTD-implicated genes in the TGF-β/SMAD pathway, valve and annulus regulators, cytoskeletal and myocyte-coupling proteins, and extracellular matrix components, while incorporating emerging CTD modifiers that expand the spectrum of arrhythmia susceptibility. Summary Recognition of CTDs as both vascular and electrical disorders reframes clinical management. Imaging markers such as mitral annular disjunction and diffuse fibrosis, together with targeted ambulatory rhythm monitoring and consideration of genetic context, may improve recognition of higher-risk phenotypes. Therapeutic strategies must balance arrhythmia control with procedural risk in fragile connective tissue substrates.
Conclusions
By unifying genetic, mechanistic, and clinical insights, this review provides an integrated framework for understanding arrhythmias in CTDs. It underscores the need for prospective registries and genotype-phenotype studies to refine surveillance and prevention strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ, United States.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Zitieren
APA
Dreher, L., Abdul Nabi, H., Ibrahim, R., Abdelnabi, M., Baqal, O., Kanaan, C. N., Tan, M. C., Baudhuin, L. M., Shamoun, F. E., & El Masry, H. Z. (2026). Connective tissue disorders and cardiac arrhythmias: genetic pathways, mechanistic bridges, and clinical implications. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1860012
Vancouver
Dreher L, Abdul Nabi H, Ibrahim R, Abdelnabi M, Baqal O, Kanaan CN, et al. Connective tissue disorders and cardiac arrhythmias: genetic pathways, mechanistic bridges, and clinical implications. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1860012
BibTeX
@article{Dreher2026,
author = {Dreher, Luke and Abdul Nabi, Hussein and Ibrahim, Ramzi and Abdelnabi, Mahmoud and Baqal, Omar and Kanaan, Christopher N and Tan, Min Choon and Baudhuin, Linnea M and Shamoun, Fadi E and El Masry, Hicham Z},
title = {Connective tissue disorders and cardiac arrhythmias: genetic pathways, mechanistic bridges, and clinical implications},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1860012}
}
EUVIMED